Michelle Carr, Author at BioTuesdays

Developments

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

OS Therapies (NYSE-A:OSTX) has announced positive data from its Phase 2b clinical trial of OST-HER2, its targeted immunotherapy candidate, in the rare, pediatric-designated indication of preventing recurrent, fully...

January 15, 2025

Developments

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

Firefly Neuroscience (NASDAQ:AIFF) has announced the discovery of a novel biomarker capable of estimating the biological age of a patient’s brain through its FDA-cleared Brain Network Analytics (BNA) technology platform...

January 14, 2025

Developments

ORIC enters into clinical supply agreement with Janssen

ORIC Pharmaceuticals (NASDAQ:ORIC) has announced a supply agreement with Janssen Research & Development to evaluate ORIC-114, a brain penetrant, oral bioavailable, irreversible EGFR/HER2 inhibitor, in combination...

January 14, 2025

Executive Moves

Piper Sandler adds John Kerins to healthcare investment banking team

Leading investment bank Piper Sandler has announced the appointment of John Kerins as a managing director on its healthcare investment banking team. In this role, he will serve pharma services clients from the firm’s...

January 14, 2025

Developments

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

Closely-held Clear Labs announced the successful completion of a $30 million series D financing round aimed at accelerating the development and adoption of its cutting-edge sequencing solutions. According to Clear Labs...

January 13, 2025

Developments

Biovica expands services with major TKa testing order

Biovica International (STO:BIOVIC-B; STO:BIOVIC.B; FRA:911) has announced the signing of a significant work order for TKa testing services, valued at 2.3 MSEK. The agreement has been made with a UK-based...

January 13, 2025

Markets

Light AI goes public on CBOE Canada, stock rallies on first day of trading

Light AI (CBOE CA: ALGO) announced the completion of its IPO (including the agents’ full exercise of their over-allotment option) and began trading on CBOE Canada today. Including the units sold pursuant to the over...

January 8, 2025

Markets

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Lake Street Capital Markets senior research analyst, Ben Haynor, issued a research note today on Profound Medical (NASDAQ:PROF; TSX:PRN), reiterating his ‘buy’ rating and $17 target price on the company’s stock...

January 2, 2025

Executive Moves

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Karyopharm Therapeutics (NASDAQ: KPTI) has announced the appointment of Lori Macomber as executive vice president (EVP), chief financial officer (CFO), and treasurer, effective January 3, 2025. Ms. Macomber, who will be...

January 2, 2025

Executive Moves

Veteran life science equity analyst Chad Messer joins Lake Street Capital Markets

Seasoned life science equity analyst, Chad Messer, Ph.D., has joined Lake Street Capital Markets as a managing director of equity research. Based in New York, Dr. Messer has over two decades of experience spanning...

January 2, 2025

Author - Michelle Carr

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

ORIC enters into clinical supply agreement with Janssen

Piper Sandler adds John Kerins to healthcare investment banking team

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

Biovica expands services with major TKa testing order

Light AI goes public on CBOE Canada, stock rallies on first day of trading

Lake Street analyst pitches Profound Medical as one of his ‘best ideas’ for 2025

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Veteran life science equity analyst Chad Messer joins Lake Street Capital Markets

Subscribe